Pressrelease
Linköping, 2025-06-26

BioReperia provides key in vivo validation in AML study published in *Leukemia*

BioReperia announces its contribution to a recently published scientific study in *Leukemia*, a prestigious journal in hematology and oncology. The study strengthens the validation of DCPS as a therapeutic target for Acute Myeloid Leukemia (AML) and marks an important milestone toward more effective and personalized cancer treatments.

The publication is a collaboration between Sprint Bioscience AB, research groups at Karolinska Institutet, NeoTargets AB, and BioReperia AB. BioReperia's role in the project was to generate critical PDX in vivo data using its proprietary ZTX® platform, which enables fast, reproducible, and individualized cancer modeling. The in vivo results confirmed and reinforced previous in vitro findings and supported the translational potential of the DCPS guided therapeutic strategy, contributing significantly to the study's scientific robustness.

"We're proud that our technology played a role in advancing a potential new treatment for AML patients. This collaboration highlights how in vivo validation can accelerate the development of targeted therapies," says Anna Erkstam, CEO of BioReperia.

The study identifies specific AML subtypes—those with DNMT3a and FLT3 ITD mutations and low FHIT expression—as particularly sensitive to DCPS inhibition. With minimal off-target effects on healthy cells, DCPS inhibitors show promise as safe and effective therapies for AML.

The research was partly funded by the Swedish Foundation for Strategic Research (SSF) and showcases the value of collaboration across biotech, academia, and applied translational technologies.

The publication is available here: https://www.nature.com/articles/s41375-025-02661-z

For more information, please contact:
Anna Erkstam
CEO, BioReperia AB
+46793322141
anna.erkstam@bioreperia.com
www.bioreperia.com